Cytokinetics - CYTK Stock Forecast, Price & News

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on CYTK shares. The Goldman Sachs Group decreased their target price on Cytokinetics from $71.00 to $57.00 and set a "buy" rating for the company in a research report on Tuesday, May 24th. Needham & Company LLC lifted their target price on Cytokinetics from $52.00 to $60.00 in a research report on Thursday, May 5th. HC Wainwright reaffirmed a "buy" rating and set a $75.00 target price on shares of Cytokinetics in a research report on Tuesday, May 24th. Mizuho boosted their price target on Cytokinetics from $54.00 to $80.00 and gave the stock a "buy" rating in a research report on Monday, May 16th. Finally, Piper Sandler boosted their price target on Cytokinetics from $50.00 to $72.00 and gave the stock an "overweight" rating in a research report on Thursday, June 9th. One investment analyst has rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $59.00.

Cytokinetics Stock Up 1.7 %

Shares of CYTK Stock opened at $50.30 on Monday. Cytokinetics has a 1-year low of $29.10 and a 1-year high of $54.74. The stock's fifty day moving average price is $43.42 and its 200 day moving average price is $39.71. The company has a debt-to-equity ratio of 1.77, a quick ratio of 9.01 and a current ratio of 9.01.

Cytokinetics (NASDAQ:CYTK - Get Rating) last announced its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($1.04) by $0.81. Cytokinetics had a negative return on equity of 118.37% and a negative net margin of 142.85%. The firm had revenue of $88.97 million for the quarter, compared to the consensus estimate of $3.73 million. During the same period in the previous year, the business earned ($0.86) EPS. The firm's revenue for the quarter was up 3029.4% on a year-over-year basis. Sell-side analysts anticipate that Cytokinetics will post -3.8 EPS for the current fiscal year.

Insider Buying and Selling at Cytokinetics

In other Cytokinetics news, CEO Robert I. Blum sold 10,000 shares of the business's stock in a transaction dated Wednesday, July 6th. The stock was sold at an average price of $44.38, for a total transaction of $443,800.00. Following the sale, the chief executive officer now owns 409,472 shares in the company, valued at approximately $18,172,367.36. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Cytokinetics news, CEO Robert I. Blum sold 10,000 shares of the business's stock in a transaction dated Wednesday, July 6th. The stock was sold at an average price of $44.38, for a total transaction of $443,800.00. Following the sale, the chief executive officer now owns 409,472 shares in the company, valued at approximately $18,172,367.36. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Fady Ibraham Malik sold 21,500 shares of the business's stock in a transaction dated Thursday, July 14th. The shares were sold at an average price of $43.43, for a total value of $933,745.00. Following the sale, the executive vice president now owns 168,346 shares in the company, valued at approximately $7,311,266.78. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 61,500 shares of company stock worth $2,607,345. 5.00% of the stock is currently owned by insiders.